Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS

Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS

Annual-Meeting

10 months
279 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS .
Up Next Autoplay